rAAV2-ND4

DRUG4 trials

Conditions

Acute LHONLeber Hereditary Optic NeuropathyLeber Hereditary Optic Neuropathy (LHON)Onset Between 12 to 24 MonthsOnset Between 24 to 60 MonthsOnset Between 3 to 6 MonthsOnset Between 6 to 12 MonthsOnset Over 60 Months

Phase 2

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

NCT03153293

Huazhong University of Science and TechnologyLeber Hereditary Optic Neuropathy

Start: 2017-12-27End: 2025-01-15Updated: 2020-09-17

Phase 3

A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation

Active, not recruitingNCT07406854

Wuhan Neurophth Biotechnology Limited CompanyLeber Hereditary Optic Neuropathy (LHON)

Start: 2024-09-19End: 2030-05-30Updated: 2026-02-12

Unknown Phase

Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)

CompletedNCT01267422

Bin LiLeber Hereditary Optic Neuropathy

Start: 2011-04-30End: 2015-11-30Updated: 2018-01-31

Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months

NCT03428178

Bin LiAcute LHON, Onset Between 12 to 24 Months, Onset Between 24 to 60 Months +4

Start: 2018-01-08End: 2020-12-30Updated: 2020-07-29

International Ophthalmology Clinics2021-09-2827 citations

Seven-Year Follow-up of Gene Therapy for Leber’s Hereditary Optic Neuropathy

Ophthalmology2020-02-2558 citations

What are the characteristics and progression of visual field defects in patients with Leber hereditary optic neuropathy: a prospective single-centre study in China

BMJ Open2019-03-0110 citations

rAAV2-ND4

Sponsors

Conditions

Phase 2

Phase 3

Unknown Phase

Related Papers